{ "source": "Nasdaq Nordic Company News", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "status": "retrieved", "company": "Oncopeptides", "reports": [ { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:09:47Z", "company": "Oncopeptides AB", "title": "Oncopeptides publishes Q1 report 2026", "category": "Interim report (Q1 and Q3)", "date": "2026-05-13", "language": "en", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "period": "2026-q1", "report_key": "2026:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=ba63c728cd2dc5f5244354cfbe38d3551&lang=en&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2026-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2026-q1\\release.txt", "attachments": [ { "label": "Press Release Q1 Report 2026.pdf", "url": "https://attachment.news.eu.nasdaq.com/a3176a061202264e1331cd27c5dff1c30", "final_url": "https://attachment.news.eu.nasdaq.com/a3176a061202264e1331cd27c5dff1c30", "filename": "Press_Release_Q1_Report_2026.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2026-q1\\Press_Release_Q1_Report_2026.pdf", "content_type": "application/pdf", "size": 134787, "sha256": "4aaf2fbcfc3d9ca6b5e46f06d9ce11e5b1ca3fd1fcb1600bf043c3a208f73ad8", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2026-q1\\Press_Release_Q1_Report_2026.pdf", "filename": "Press_Release_Q1_Report_2026.pdf", "extension": ".pdf", "size": 134787, "sha256": "4aaf2fbcfc3d9ca6b5e46f06d9ce11e5b1ca3fd1fcb1600bf043c3a208f73ad8", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2026-q1\\extracted\\Press_Release_Q1_Report_2026\\Press_Release_Q1_Report_2026.txt", "text_chars": 9854, "metadata": { "page_count": 5, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2026-q1\\extracted\\Press_Release_Q1_Report_2026\\Press_Release_Q1_Report_2026.extraction.json" } }, { "label": "Interim Report Q1 2026 Oncopeptides AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/a640a22fadfde25cdc5f072a65785de3a", "final_url": "https://attachment.news.eu.nasdaq.com/a640a22fadfde25cdc5f072a65785de3a", "filename": "Interim_Report_Q1_2026_Oncopeptides_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2026-q1\\Interim_Report_Q1_2026_Oncopeptides_AB.pdf", "content_type": "application/pdf", "size": 629429, "sha256": "26bd05e351472334f0496a128c4ae5d62c86cb43231271c4e277ef9da186d84b", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2026-q1\\Interim_Report_Q1_2026_Oncopeptides_AB.pdf", "filename": "Interim_Report_Q1_2026_Oncopeptides_AB.pdf", "extension": ".pdf", "size": 629429, "sha256": "26bd05e351472334f0496a128c4ae5d62c86cb43231271c4e277ef9da186d84b", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2026-q1\\extracted\\Interim_Report_Q1_2026_Oncopeptides_AB\\Interim_Report_Q1_2026_Oncopeptides_AB.txt", "text_chars": 20704, "metadata": { "page_count": 10, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2026-q1\\extracted\\Interim_Report_Q1_2026_Oncopeptides_AB\\Interim_Report_Q1_2026_Oncopeptides_AB.extraction.json" } } ], "announcement_id": "1441833", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:10:01Z", "company": "Oncopeptides AB", "title": "Oncopeptides publicerar årsredovisningen för 2025", "category": "Bokslut och Verksamhetsberättelse", "date": "2026-04-28", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "period": "2025-annual", "report_key": "2025:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b59e2f33e874bdad672aac3a861f27e35&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-annual\\release.txt", "attachments": [ { "label": "Pressmeddelande Arsredovisning 2025 Se.pdf", "url": "https://attachment.news.eu.nasdaq.com/ace495fcb6edc8a8d03663d12906fec1d", "final_url": "https://attachment.news.eu.nasdaq.com/ace495fcb6edc8a8d03663d12906fec1d", "filename": "Pressmeddelande_Arsredovisning_2025_Se.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-annual\\Pressmeddelande_Arsredovisning_2025_Se.pdf", "content_type": "application/pdf", "size": 52808, "sha256": "c40f767c44052e916e2886060155177f396a43385ae336d5a1ebdaaf56703f76", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-annual\\Pressmeddelande_Arsredovisning_2025_Se.pdf", "filename": "Pressmeddelande_Arsredovisning_2025_Se.pdf", "extension": ".pdf", "size": 52808, "sha256": "c40f767c44052e916e2886060155177f396a43385ae336d5a1ebdaaf56703f76", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-annual\\extracted\\Pressmeddelande_Arsredovisning_2025_Se\\Pressmeddelande_Arsredovisning_2025_Se.txt", "text_chars": 2485, "metadata": { "page_count": 2, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-annual\\extracted\\Pressmeddelande_Arsredovisning_2025_Se\\Pressmeddelande_Arsredovisning_2025_Se.extraction.json" } }, { "label": "Arsredovisning 2025 260428 Se.pdf", "url": "https://attachment.news.eu.nasdaq.com/ad8459a263a0e8ceb0fe0e33b3425b0e7", "final_url": "https://attachment.news.eu.nasdaq.com/ad8459a263a0e8ceb0fe0e33b3425b0e7", "filename": "Arsredovisning_2025_260428_Se.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-annual\\Arsredovisning_2025_260428_Se.pdf", "content_type": "application/pdf", "size": 2917823, "sha256": "20d4aa61cf83a6cd35f30949b5834bde2b21e8347a3c91a4002177ce23079bba", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-annual\\Arsredovisning_2025_260428_Se.pdf", "filename": "Arsredovisning_2025_260428_Se.pdf", "extension": ".pdf", "size": 2917823, "sha256": "20d4aa61cf83a6cd35f30949b5834bde2b21e8347a3c91a4002177ce23079bba", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-annual\\extracted\\Arsredovisning_2025_260428_Se\\Arsredovisning_2025_260428_Se.txt", "text_chars": 246195, "metadata": { "page_count": 74, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-annual\\extracted\\Arsredovisning_2025_260428_Se\\Arsredovisning_2025_260428_Se.extraction.json" } } ], "announcement_id": "1437860", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:10:08Z", "company": "Oncopeptides AB", "title": "Oncopeptides publicerar bokslutskommunikén för 2025", "category": "Bokslutskommuniké", "date": "2026-02-19", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "period": "2025-q4", "report_key": "2025:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b39c83566f4cd28de866c50e1fc3b8419&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q4\\release.txt", "attachments": [ { "label": "Pressmeddelande Q4 Rapport 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a3f22003ea0f9ff5abe99f0175f908608", "final_url": "https://attachment.news.eu.nasdaq.com/a3f22003ea0f9ff5abe99f0175f908608", "filename": "Pressmeddelande_Q4_Rapport_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q4\\Pressmeddelande_Q4_Rapport_2025.pdf", "content_type": "application/pdf", "size": 118845, "sha256": "a7331e47b8ec16bf4e06d67d9075abde7db1e530202a7997fdd63ed4bf05fe3b", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q4\\Pressmeddelande_Q4_Rapport_2025.pdf", "filename": "Pressmeddelande_Q4_Rapport_2025.pdf", "extension": ".pdf", "size": 118845, "sha256": "a7331e47b8ec16bf4e06d67d9075abde7db1e530202a7997fdd63ed4bf05fe3b", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q4\\extracted\\Pressmeddelande_Q4_Rapport_2025\\Pressmeddelande_Q4_Rapport_2025.txt", "text_chars": 10128, "metadata": { "page_count": 5, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q4\\extracted\\Pressmeddelande_Q4_Rapport_2025\\Pressmeddelande_Q4_Rapport_2025.extraction.json" } }, { "label": "Bokslutskommunike 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a009c174c018035acc6195b9c762a26a9", "final_url": "https://attachment.news.eu.nasdaq.com/a009c174c018035acc6195b9c762a26a9", "filename": "Bokslutskommunike_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q4\\Bokslutskommunike_2025.pdf", "content_type": "application/pdf", "size": 776444, "sha256": "320e8f30e1760f76f8ac269eadfcaa43bbe21db53b07296d0db8c2c81c8c7992", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q4\\Bokslutskommunike_2025.pdf", "filename": "Bokslutskommunike_2025.pdf", "extension": ".pdf", "size": 776444, "sha256": "320e8f30e1760f76f8ac269eadfcaa43bbe21db53b07296d0db8c2c81c8c7992", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q4\\extracted\\Bokslutskommunike_2025\\Bokslutskommunike_2025.txt", "text_chars": 21313, "metadata": { "page_count": 10, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q4\\extracted\\Bokslutskommunike_2025\\Bokslutskommunike_2025.extraction.json" } } ], "announcement_id": "1421251", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:10:18Z", "company": "Oncopeptides AB", "title": "Oncopeptides publishes Q3 report 2025", "category": "Interim report (Q1 and Q3)", "date": "2025-11-05", "language": "en", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "period": "2025-q3", "report_key": "2025:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b3ed817c232647a7306ed557fd1247346&lang=en&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q3\\release.txt", "attachments": [ { "label": "Press Release Q3 Report 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a8f573d8d9766430cc6e97964572aa73d", "final_url": "https://attachment.news.eu.nasdaq.com/a8f573d8d9766430cc6e97964572aa73d", "filename": "Press_Release_Q3_Report_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q3\\Press_Release_Q3_Report_2025.pdf", "content_type": "application/pdf", "size": 116089, "sha256": "b1d7548da22231d6c2bc8f5defac890151320ec8428fa3eed41616dc15293788", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q3\\Press_Release_Q3_Report_2025.pdf", "filename": "Press_Release_Q3_Report_2025.pdf", "extension": ".pdf", "size": 116089, "sha256": "b1d7548da22231d6c2bc8f5defac890151320ec8428fa3eed41616dc15293788", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q3\\extracted\\Press_Release_Q3_Report_2025\\Press_Release_Q3_Report_2025.txt", "text_chars": 9386, "metadata": { "page_count": 5, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q3\\extracted\\Press_Release_Q3_Report_2025\\Press_Release_Q3_Report_2025.extraction.json" } }, { "label": "Q3 Report 2025 Oncopeptides AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac855f4271b5a776cd2a4f4c5c172f305", "final_url": "https://attachment.news.eu.nasdaq.com/ac855f4271b5a776cd2a4f4c5c172f305", "filename": "Q3_Report_2025_Oncopeptides_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q3\\Q3_Report_2025_Oncopeptides_AB.pdf", "content_type": "application/pdf", "size": 651229, "sha256": "9491cff09c4ba348f5b343f6d21419ffa79d2a2fd1d32733ad72b7a6f0dd7505", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q3\\Q3_Report_2025_Oncopeptides_AB.pdf", "filename": "Q3_Report_2025_Oncopeptides_AB.pdf", "extension": ".pdf", "size": 651229, "sha256": "9491cff09c4ba348f5b343f6d21419ffa79d2a2fd1d32733ad72b7a6f0dd7505", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q3\\extracted\\Q3_Report_2025_Oncopeptides_AB\\Q3_Report_2025_Oncopeptides_AB.txt", "text_chars": 23475, "metadata": { "page_count": 11, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q3\\extracted\\Q3_Report_2025_Oncopeptides_AB\\Q3_Report_2025_Oncopeptides_AB.extraction.json" } } ], "announcement_id": "1398736", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:10:27Z", "company": "Oncopeptides AB", "title": "Oncopeptides publicerar rapporten för det andra kvartalet 2025", "category": "Halvårsrapport", "date": "2025-08-21", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "period": "2025-q2", "report_key": "2025:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b3341027f6cbd0253df72b48fce2f79cf&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q2\\release.txt", "attachments": [ { "label": "Pressmeddelande Q2 Rapport 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a36358a7c72446fe9ecdd70259ca2c242", "final_url": "https://attachment.news.eu.nasdaq.com/a36358a7c72446fe9ecdd70259ca2c242", "filename": "Pressmeddelande_Q2_Rapport_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q2\\Pressmeddelande_Q2_Rapport_2025.pdf", "content_type": "application/pdf", "size": 115541, "sha256": "98cba464bdddc5fe6b26dd7451e90054bd75361f2802463c2fde2bf34455fd5b", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q2\\Pressmeddelande_Q2_Rapport_2025.pdf", "filename": "Pressmeddelande_Q2_Rapport_2025.pdf", "extension": ".pdf", "size": 115541, "sha256": "98cba464bdddc5fe6b26dd7451e90054bd75361f2802463c2fde2bf34455fd5b", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q2\\extracted\\Pressmeddelande_Q2_Rapport_2025\\Pressmeddelande_Q2_Rapport_2025.txt", "text_chars": 9124, "metadata": { "page_count": 4, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q2\\extracted\\Pressmeddelande_Q2_Rapport_2025\\Pressmeddelande_Q2_Rapport_2025.extraction.json" } }, { "label": "Q2 Rapport 2025 Oncopeptides AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/a10493486bbc8a9087ef3c90e5cb50d5a", "final_url": "https://attachment.news.eu.nasdaq.com/a10493486bbc8a9087ef3c90e5cb50d5a", "filename": "Q2_Rapport_2025_Oncopeptides_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q2\\Q2_Rapport_2025_Oncopeptides_AB.pdf", "content_type": "application/pdf", "size": 594811, "sha256": "7651de6672d75b6d9d2938f6b81f2a272aa5b1116fbde1293e9e67f97de59237", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q2\\Q2_Rapport_2025_Oncopeptides_AB.pdf", "filename": "Q2_Rapport_2025_Oncopeptides_AB.pdf", "extension": ".pdf", "size": 594811, "sha256": "7651de6672d75b6d9d2938f6b81f2a272aa5b1116fbde1293e9e67f97de59237", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q2\\extracted\\Q2_Rapport_2025_Oncopeptides_AB\\Q2_Rapport_2025_Oncopeptides_AB.txt", "text_chars": 20247, "metadata": { "page_count": 10, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q2\\extracted\\Q2_Rapport_2025_Oncopeptides_AB\\Q2_Rapport_2025_Oncopeptides_AB.extraction.json" } } ], "announcement_id": "1384419", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:10:38Z", "company": "Oncopeptides AB", "title": "Oncopeptides publishes Q1 report 2025", "category": "Interim report (Q1 and Q3)", "date": "2025-05-15", "language": "en", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "period": "2025-q1", "report_key": "2025:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=bbee942e56623baa793739e2e2e09f2f6&lang=en&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q1\\release.txt", "attachments": [ { "label": "Interim Report Q1 2025 Oncopeptides AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/ab8595f10b25ed5bbcdb9f37eff2bbeb3", "final_url": "https://attachment.news.eu.nasdaq.com/ab8595f10b25ed5bbcdb9f37eff2bbeb3", "filename": "Interim_Report_Q1_2025_Oncopeptides_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q1\\Interim_Report_Q1_2025_Oncopeptides_AB.pdf", "content_type": "application/pdf", "size": 498493, "sha256": "104d2a975270a2f51b1a1dbd9c25fefccc292e66d0bdf0d80ae2ce31b8efb89c", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q1\\Interim_Report_Q1_2025_Oncopeptides_AB.pdf", "filename": "Interim_Report_Q1_2025_Oncopeptides_AB.pdf", "extension": ".pdf", "size": 498493, "sha256": "104d2a975270a2f51b1a1dbd9c25fefccc292e66d0bdf0d80ae2ce31b8efb89c", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q1\\extracted\\Interim_Report_Q1_2025_Oncopeptides_AB\\Interim_Report_Q1_2025_Oncopeptides_AB.txt", "text_chars": 20831, "metadata": { "page_count": 10, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q1\\extracted\\Interim_Report_Q1_2025_Oncopeptides_AB\\Interim_Report_Q1_2025_Oncopeptides_AB.extraction.json" } }, { "label": "Press Release Q1 Report 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a633952f2c5ee6e3784e10cfc2bf40b28", "final_url": "https://attachment.news.eu.nasdaq.com/a633952f2c5ee6e3784e10cfc2bf40b28", "filename": "Press_Release_Q1_Report_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q1\\Press_Release_Q1_Report_2025.pdf", "content_type": "application/pdf", "size": 114896, "sha256": "d0225a1b6ce41d3c2d97c4cd1c0221bc774868296d0a28590e7685be437bb829", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q1\\Press_Release_Q1_Report_2025.pdf", "filename": "Press_Release_Q1_Report_2025.pdf", "extension": ".pdf", "size": 114896, "sha256": "d0225a1b6ce41d3c2d97c4cd1c0221bc774868296d0a28590e7685be437bb829", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q1\\extracted\\Press_Release_Q1_Report_2025\\Press_Release_Q1_Report_2025.txt", "text_chars": 9177, "metadata": { "page_count": 5, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2025-q1\\extracted\\Press_Release_Q1_Report_2025\\Press_Release_Q1_Report_2025.extraction.json" } } ], "announcement_id": "1363398", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:10:49Z", "company": "Oncopeptides AB", "title": "Oncopeptides publicerar årsredovisningen för 2024", "category": "Bokslut och Verksamhetsberättelse", "date": "2025-04-28", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "period": "2024-annual", "report_key": "2024:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b0ca885f7156672f7cb4a5e25da46b360&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-annual\\release.txt", "attachments": [ { "label": "Arsredovisning 2024 Oncopeptides AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/afb04baf8ae0ac2231f36921bc3d4d8d9", "final_url": "https://attachment.news.eu.nasdaq.com/afb04baf8ae0ac2231f36921bc3d4d8d9", "filename": "Arsredovisning_2024_Oncopeptides_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-annual\\Arsredovisning_2024_Oncopeptides_AB.pdf", "content_type": "application/pdf", "size": 1876227, "sha256": "1640dd577580d93bfbd18edbb969556c84b6c456ee499e51a6fcd60cadee3406", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-annual\\Arsredovisning_2024_Oncopeptides_AB.pdf", "filename": "Arsredovisning_2024_Oncopeptides_AB.pdf", "extension": ".pdf", "size": 1876227, "sha256": "1640dd577580d93bfbd18edbb969556c84b6c456ee499e51a6fcd60cadee3406", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-annual\\extracted\\Arsredovisning_2024_Oncopeptides_AB\\Arsredovisning_2024_Oncopeptides_AB.txt", "text_chars": 269301, "metadata": { "page_count": 74, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-annual\\extracted\\Arsredovisning_2024_Oncopeptides_AB\\Arsredovisning_2024_Oncopeptides_AB.extraction.json" } }, { "label": "Pressmeddelande Arsredovisning 2024 Oncopeptides AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/a30a2a6a130a91ce745625bd6fa474504", "final_url": "https://attachment.news.eu.nasdaq.com/a30a2a6a130a91ce745625bd6fa474504", "filename": "Pressmeddelande_Arsredovisning_2024_Oncopeptides_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-annual\\Pressmeddelande_Arsredovisning_2024_Oncopeptides_AB.pdf", "content_type": "application/pdf", "size": 52685, "sha256": "abe9308acb82a7166883e5cd79e1764d45d64c0b21f130e986bc90c008c477c5", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-annual\\Pressmeddelande_Arsredovisning_2024_Oncopeptides_AB.pdf", "filename": "Pressmeddelande_Arsredovisning_2024_Oncopeptides_AB.pdf", "extension": ".pdf", "size": 52685, "sha256": "abe9308acb82a7166883e5cd79e1764d45d64c0b21f130e986bc90c008c477c5", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-annual\\extracted\\Pressmeddelande_Arsredovisning_2024_Oncopepti\\Pressmeddelande_Arsredovisning_2024_Oncopeptides_A.txt", "text_chars": 2398, "metadata": { "page_count": 2, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-annual\\extracted\\Pressmeddelande_Arsredovisning_2024_Oncopepti\\Pressmeddelande_Arsredovisning_2024_Oncopeptides_A.extraction.json" } } ], "announcement_id": "1358745", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:11:01Z", "company": "Oncopeptides AB", "title": "Oncopeptides publicerar bokslutskommunikén för 2024", "category": "Bokslutskommuniké", "date": "2025-02-27", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "period": "2024-q4", "report_key": "2024:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b7726cd82bed86c978145f2c163d6d9d5&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q4\\release.txt", "attachments": [ { "label": "Bokslutskommunike 2024 Oncopeptides AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/a620844aaae3c8c829e35bd0c666d17f6", "final_url": "https://attachment.news.eu.nasdaq.com/a620844aaae3c8c829e35bd0c666d17f6", "filename": "Bokslutskommunike_2024_Oncopeptides_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q4\\Bokslutskommunike_2024_Oncopeptides_AB.pdf", "content_type": "application/pdf", "size": 599351, "sha256": "24cdb5a54e134e6bd455a87673cd68ea9b8088aaf89f0647c11f697be74c25a8", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q4\\Bokslutskommunike_2024_Oncopeptides_AB.pdf", "filename": "Bokslutskommunike_2024_Oncopeptides_AB.pdf", "extension": ".pdf", "size": 599351, "sha256": "24cdb5a54e134e6bd455a87673cd68ea9b8088aaf89f0647c11f697be74c25a8", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q4\\extracted\\Bokslutskommunike_2024_Oncopeptides_AB\\Bokslutskommunike_2024_Oncopeptides_AB.txt", "text_chars": 26255, "metadata": { "page_count": 10, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q4\\extracted\\Bokslutskommunike_2024_Oncopeptides_AB\\Bokslutskommunike_2024_Oncopeptides_AB.extraction.json" } }, { "label": "Pressmeddelande bokslutskommuniken 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/aeabb5ef4afcb139c59b6b6c48e42124d", "final_url": "https://attachment.news.eu.nasdaq.com/aeabb5ef4afcb139c59b6b6c48e42124d", "filename": "Pressmeddelande_bokslutskommuniken_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q4\\Pressmeddelande_bokslutskommuniken_2024.pdf", "content_type": "application/pdf", "size": 187084, "sha256": "d625117e4e8bb6eb1cc85fa0620c4a447e6b60737dea0a4182939488d88f472f", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q4\\Pressmeddelande_bokslutskommuniken_2024.pdf", "filename": "Pressmeddelande_bokslutskommuniken_2024.pdf", "extension": ".pdf", "size": 187084, "sha256": "d625117e4e8bb6eb1cc85fa0620c4a447e6b60737dea0a4182939488d88f472f", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q4\\extracted\\Pressmeddelande_bokslutskommuniken_2024\\Pressmeddelande_bokslutskommuniken_2024.txt", "text_chars": 11322, "metadata": { "page_count": 5, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q4\\extracted\\Pressmeddelande_bokslutskommuniken_2024\\Pressmeddelande_bokslutskommuniken_2024.extraction.json" } } ], "announcement_id": "1345605", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:11:10Z", "company": "Oncopeptides AB", "title": "Oncopeptides publishes Q3 report 2024", "category": "Interim report (Q1 and Q3)", "date": "2024-11-07", "language": "en", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "period": "2024-q3", "report_key": "2024:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b88749bc5de7afa92caff80b7ea0317fe&lang=en&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q3\\release.txt", "attachments": [ { "label": "Q3 Report 2024 Oncopeptides AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/a7cdc25bf84d076ff5cb18e3dcf190981", "final_url": "https://attachment.news.eu.nasdaq.com/a7cdc25bf84d076ff5cb18e3dcf190981", "filename": "Q3_Report_2024_Oncopeptides_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q3\\Q3_Report_2024_Oncopeptides_AB.pdf", "content_type": "application/pdf", "size": 919300, "sha256": "6d8f6d32ed2185c96f327cdb7e3c9abe54ef63a699b1de5730cffea9a446c0ba", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q3\\Q3_Report_2024_Oncopeptides_AB.pdf", "filename": "Q3_Report_2024_Oncopeptides_AB.pdf", "extension": ".pdf", "size": 919300, "sha256": "6d8f6d32ed2185c96f327cdb7e3c9abe54ef63a699b1de5730cffea9a446c0ba", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q3\\extracted\\Q3_Report_2024_Oncopeptides_AB\\Q3_Report_2024_Oncopeptides_AB.txt", "text_chars": 34486, "metadata": { "page_count": 11, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q3\\extracted\\Q3_Report_2024_Oncopeptides_AB\\Q3_Report_2024_Oncopeptides_AB.extraction.json" } }, { "label": "Press Release Q3 Report 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac9b55df7f79dafbf60f2f482f9b524ea", "final_url": "https://attachment.news.eu.nasdaq.com/ac9b55df7f79dafbf60f2f482f9b524ea", "filename": "Press_Release_Q3_Report_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q3\\Press_Release_Q3_Report_2024.pdf", "content_type": "application/pdf", "size": 191818, "sha256": "e97f7b9f559daea0428eb1139bb999eae689fda8fa34be59bbebf73e0640e765", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q3\\Press_Release_Q3_Report_2024.pdf", "filename": "Press_Release_Q3_Report_2024.pdf", "extension": ".pdf", "size": 191818, "sha256": "e97f7b9f559daea0428eb1139bb999eae689fda8fa34be59bbebf73e0640e765", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q3\\extracted\\Press_Release_Q3_Report_2024\\Press_Release_Q3_Report_2024.txt", "text_chars": 8024, "metadata": { "page_count": 4, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q3\\extracted\\Press_Release_Q3_Report_2024\\Press_Release_Q3_Report_2024.extraction.json" } } ], "announcement_id": "1326369", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:11:20Z", "company": "Oncopeptides AB", "title": "Oncopeptides publicerar rapporten för det andra kvartalet 2024", "category": "Halvårsrapport", "date": "2024-08-14", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "period": "2024-q2", "report_key": "2024:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=be6857c6667761c38a1e3ff2e7906fdf6&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q2\\release.txt", "attachments": [ { "label": "Q2 Rapport 2024 Oncopeptides AB publ.pdf", "url": "https://attachment.news.eu.nasdaq.com/a952a4b468952249f0f72429e317671b9", "final_url": "https://attachment.news.eu.nasdaq.com/a952a4b468952249f0f72429e317671b9", "filename": "Q2_Rapport_2024_Oncopeptides_AB_publ.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q2\\Q2_Rapport_2024_Oncopeptides_AB_publ.pdf", "content_type": "application/pdf", "size": 575826, "sha256": "2fb9c2eb83d318f884550d60c72ca62540133b468c579722b628dc4d85b0bab4", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q2\\Q2_Rapport_2024_Oncopeptides_AB_publ.pdf", "filename": "Q2_Rapport_2024_Oncopeptides_AB_publ.pdf", "extension": ".pdf", "size": 575826, "sha256": "2fb9c2eb83d318f884550d60c72ca62540133b468c579722b628dc4d85b0bab4", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q2\\extracted\\Q2_Rapport_2024_Oncopeptides_AB_publ\\Q2_Rapport_2024_Oncopeptides_AB_publ.txt", "text_chars": 31881, "metadata": { "page_count": 10, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q2\\extracted\\Q2_Rapport_2024_Oncopeptides_AB_publ\\Q2_Rapport_2024_Oncopeptides_AB_publ.extraction.json" } }, { "label": "Pressmeddelande Q2 Rapport 2024.pdf", "url": "https://attachment.news.eu.nasdaq.com/ad1fffd59806350f9f1ab1fc15959bb41", "final_url": "https://attachment.news.eu.nasdaq.com/ad1fffd59806350f9f1ab1fc15959bb41", "filename": "Pressmeddelande_Q2_Rapport_2024.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q2\\Pressmeddelande_Q2_Rapport_2024.pdf", "content_type": "application/pdf", "size": 114698, "sha256": "efa3f38f420448c9cc07f3940ee311634d7008282883d2a2a05603b555ea2308", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q2\\Pressmeddelande_Q2_Rapport_2024.pdf", "filename": "Pressmeddelande_Q2_Rapport_2024.pdf", "extension": ".pdf", "size": 114698, "sha256": "efa3f38f420448c9cc07f3940ee311634d7008282883d2a2a05603b555ea2308", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q2\\extracted\\Pressmeddelande_Q2_Rapport_2024\\Pressmeddelande_Q2_Rapport_2024.txt", "text_chars": 8982, "metadata": { "page_count": 4, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q2\\extracted\\Pressmeddelande_Q2_Rapport_2024\\Pressmeddelande_Q2_Rapport_2024.extraction.json" } } ], "announcement_id": "1310623", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:11:33Z", "company": "Oncopeptides AB", "title": "Oncopeptides publishes Q1 report 2024", "category": "Interim report (Q1 and Q3)", "date": "2024-05-30", "language": "en", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "period": "2024-q1", "report_key": "2024:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=ba64a2f0da65156ccf492300a0568f195&lang=en&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q1\\release.txt", "attachments": [ { "label": "Press Release Q1 Report 2024 Oncopeptides AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/a1ff0d10358a230317612bbe900d2aa5f", "final_url": "https://attachment.news.eu.nasdaq.com/a1ff0d10358a230317612bbe900d2aa5f", "filename": "Press_Release_Q1_Report_2024_Oncopeptides_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q1\\Press_Release_Q1_Report_2024_Oncopeptides_AB.pdf", "content_type": "application/pdf", "size": 107281, "sha256": "3c0a86e12c435ab4e36e0712ac1af034c86b040fc31a113ffa0d7697fc637c1c", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q1\\Press_Release_Q1_Report_2024_Oncopeptides_AB.pdf", "filename": "Press_Release_Q1_Report_2024_Oncopeptides_AB.pdf", "extension": ".pdf", "size": 107281, "sha256": "3c0a86e12c435ab4e36e0712ac1af034c86b040fc31a113ffa0d7697fc637c1c", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q1\\extracted\\Press_Release_Q1_Report_2024_Oncopeptides_AB\\Press_Release_Q1_Report_2024_Oncopeptides_AB.txt", "text_chars": 11445, "metadata": { "page_count": 5, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q1\\extracted\\Press_Release_Q1_Report_2024_Oncopeptides_AB\\Press_Release_Q1_Report_2024_Oncopeptides_AB.extraction.json" } }, { "label": "INTERIM REPORT for Q1 2024 - Oncopeptides AB.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac36b75da49df57fed7da5dd44741856a", "final_url": "https://attachment.news.eu.nasdaq.com/ac36b75da49df57fed7da5dd44741856a", "filename": "INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q1\\INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB.pdf", "content_type": "application/pdf", "size": 537588, "sha256": "92d5dee1d7fd343fd21517f2f7513483139fba845498473e45ec278dd73160b2", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q1\\INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB.pdf", "filename": "INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB.pdf", "extension": ".pdf", "size": 537588, "sha256": "92d5dee1d7fd343fd21517f2f7513483139fba845498473e45ec278dd73160b2", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q1\\extracted\\INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB\\INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB.txt", "text_chars": 33589, "metadata": { "page_count": 9, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2024-q1\\extracted\\INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB\\INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB.extraction.json" } } ], "announcement_id": "1298941", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:11:43Z", "company": "Oncopeptides AB", "title": "Oncopeptides publicerar årsredovisningen för 2023", "category": "Bokslut och Verksamhetsberättelse", "date": "2024-04-22", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "period": "2023-annual", "report_key": "2023:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=ba0b3d56c00e10d1b5c1dbb3166308f1e&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-annual\\release.txt", "attachments": [ { "label": "Oncopeptides AB publ Arsredovisning 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/af6ea68f7a471b0d2bdac0312f245a792", "final_url": "https://attachment.news.eu.nasdaq.com/af6ea68f7a471b0d2bdac0312f245a792", "filename": "Oncopeptides_AB_publ_Arsredovisning_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-annual\\Oncopeptides_AB_publ_Arsredovisning_2023.pdf", "content_type": "application/pdf", "size": 10888925, "sha256": "5927414fddccc6e74bc7495c6be785d134a1885afed9e0eb8c686471e72067f9", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-annual\\Oncopeptides_AB_publ_Arsredovisning_2023.pdf", "filename": "Oncopeptides_AB_publ_Arsredovisning_2023.pdf", "extension": ".pdf", "size": 10888925, "sha256": "5927414fddccc6e74bc7495c6be785d134a1885afed9e0eb8c686471e72067f9", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-annual\\extracted\\Oncopeptides_AB_publ_Arsredovisning_2023\\Oncopeptides_AB_publ_Arsredovisning_2023.txt", "text_chars": 278369, "metadata": { "page_count": 76, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-annual\\extracted\\Oncopeptides_AB_publ_Arsredovisning_2023\\Oncopeptides_AB_publ_Arsredovisning_2023.extraction.json" } }, { "label": "Pressmeddelande Arsredovisning 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a270c34cdacd4d8962941a2748e1563e5", "final_url": "https://attachment.news.eu.nasdaq.com/a270c34cdacd4d8962941a2748e1563e5", "filename": "Pressmeddelande_Arsredovisning_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-annual\\Pressmeddelande_Arsredovisning_2023.pdf", "content_type": "application/pdf", "size": 53393, "sha256": "5edb30d841789b24e420020a80bd9f08188d864769de00dc3be494e3664fc436", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-annual\\Pressmeddelande_Arsredovisning_2023.pdf", "filename": "Pressmeddelande_Arsredovisning_2023.pdf", "extension": ".pdf", "size": 53393, "sha256": "5edb30d841789b24e420020a80bd9f08188d864769de00dc3be494e3664fc436", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-annual\\extracted\\Pressmeddelande_Arsredovisning_2023\\Pressmeddelande_Arsredovisning_2023.txt", "text_chars": 2806, "metadata": { "page_count": 2, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-annual\\extracted\\Pressmeddelande_Arsredovisning_2023\\Pressmeddelande_Arsredovisning_2023.extraction.json" } } ], "announcement_id": "1289540", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:11:55Z", "company": "Oncopeptides AB", "title": "Oncopeptides publicerar bokslutskommunikén för 2023", "category": "Bokslutskommuniké", "date": "2024-02-27", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "period": "2023-q4", "report_key": "2023:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b6fe088cb2d97713ccf378257a58a514e&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q4\\release.txt", "attachments": [ { "label": "Pressmeddelande Bokslutskommunike 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a069271ac08e304ad6beb774ec371e41f", "final_url": "https://attachment.news.eu.nasdaq.com/a069271ac08e304ad6beb774ec371e41f", "filename": "Pressmeddelande_Bokslutskommunike_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q4\\Pressmeddelande_Bokslutskommunike_2023.pdf", "content_type": "application/pdf", "size": 113681, "sha256": "ce7da8959506cf406997e21fc0f826f3db07642b59ac56029f2592dabddc89be", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q4\\Pressmeddelande_Bokslutskommunike_2023.pdf", "filename": "Pressmeddelande_Bokslutskommunike_2023.pdf", "extension": ".pdf", "size": 113681, "sha256": "ce7da8959506cf406997e21fc0f826f3db07642b59ac56029f2592dabddc89be", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q4\\extracted\\Pressmeddelande_Bokslutskommunike_2023\\Pressmeddelande_Bokslutskommunike_2023.txt", "text_chars": 12240, "metadata": { "page_count": 5, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q4\\extracted\\Pressmeddelande_Bokslutskommunike_2023\\Pressmeddelande_Bokslutskommunike_2023.extraction.json" } }, { "label": "Q4 Bokslutskommunike 2023 20240227.pdf", "url": "https://attachment.news.eu.nasdaq.com/a5b34b74e64e0c5e0352da16de120def7", "final_url": "https://attachment.news.eu.nasdaq.com/a5b34b74e64e0c5e0352da16de120def7", "filename": "Q4_Bokslutskommunike_2023_20240227.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q4\\Q4_Bokslutskommunike_2023_20240227.pdf", "content_type": "application/pdf", "size": 584317, "sha256": "cca77af0ef2c322e6604b48150f366fbfdaea1545b80e6c4b350263685d1f394", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q4\\Q4_Bokslutskommunike_2023_20240227.pdf", "filename": "Q4_Bokslutskommunike_2023_20240227.pdf", "extension": ".pdf", "size": 584317, "sha256": "cca77af0ef2c322e6604b48150f366fbfdaea1545b80e6c4b350263685d1f394", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q4\\extracted\\Q4_Bokslutskommunike_2023_20240227\\Q4_Bokslutskommunike_2023_20240227.txt", "text_chars": 35422, "metadata": { "page_count": 10, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q4\\extracted\\Q4_Bokslutskommunike_2023_20240227\\Q4_Bokslutskommunike_2023_20240227.extraction.json" } } ], "announcement_id": "1277522", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:12:04Z", "company": "Oncopeptides AB", "title": "Oncopeptides publishes Q3 report 2023", "category": "Interim report (Q1 and Q3)", "date": "2023-11-08", "language": "en", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "period": "2023-q3", "report_key": "2023:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b494cb61055f22fb7b563672e017a49ab&lang=en&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q3\\release.txt", "attachments": [ { "label": "Press Release Publication Q3 Report 231108 EN.pdf", "url": "https://attachment.news.eu.nasdaq.com/a797bafebec3e15fbb53effaff46b4fd5", "final_url": "https://attachment.news.eu.nasdaq.com/a797bafebec3e15fbb53effaff46b4fd5", "filename": "Press_Release_Publication_Q3_Report_231108_EN.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q3\\Press_Release_Publication_Q3_Report_231108_EN.pdf", "content_type": "application/pdf", "size": 258225, "sha256": "e6c6682147f73d6fc483cfb811ab53ba4bfcca93e6f0d63d1532f9a67a665d67", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q3\\Press_Release_Publication_Q3_Report_231108_EN.pdf", "filename": "Press_Release_Publication_Q3_Report_231108_EN.pdf", "extension": ".pdf", "size": 258225, "sha256": "e6c6682147f73d6fc483cfb811ab53ba4bfcca93e6f0d63d1532f9a67a665d67", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q3\\extracted\\Press_Release_Publication_Q3_Report_231108_EN\\Press_Release_Publication_Q3_Report_231108_EN.txt", "text_chars": 5638, "metadata": { "page_count": 2, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q3\\extracted\\Press_Release_Publication_Q3_Report_231108_EN\\Press_Release_Publication_Q3_Report_231108_EN.extraction.json" } }, { "label": "Interim Report Q3 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a1cfef8bffada0217bc4e842b5745e094", "final_url": "https://attachment.news.eu.nasdaq.com/a1cfef8bffada0217bc4e842b5745e094", "filename": "Interim_Report_Q3_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q3\\Interim_Report_Q3_2023.pdf", "content_type": "application/pdf", "size": 568945, "sha256": "0685206209f958daff1ce1a50b99bfbe38ccf9c3f2a6d3652f6f0dce6be8f5f9", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q3\\Interim_Report_Q3_2023.pdf", "filename": "Interim_Report_Q3_2023.pdf", "extension": ".pdf", "size": 568945, "sha256": "0685206209f958daff1ce1a50b99bfbe38ccf9c3f2a6d3652f6f0dce6be8f5f9", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q3\\extracted\\Interim_Report_Q3_2023\\Interim_Report_Q3_2023.txt", "text_chars": 38994, "metadata": { "page_count": 11, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q3\\extracted\\Interim_Report_Q3_2023\\Interim_Report_Q3_2023.extraction.json" } } ], "announcement_id": "1257887", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:12:14Z", "company": "Oncopeptides AB", "title": "Oncopeptides publicerar rapporten för andra kvartalet 2023", "category": "Halvårsrapport", "date": "2023-08-10", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "period": "2023-q2", "report_key": "2023:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=bc3b23b1ef100c2d078949d341a6b0417&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q2\\release.txt", "attachments": [ { "label": "Pressmeddelande Publicering Q2 Rapporten 230810 SE.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac4e8195683b3f5d071b9299a534f397e", "final_url": "https://attachment.news.eu.nasdaq.com/ac4e8195683b3f5d071b9299a534f397e", "filename": "Pressmeddelande_Publicering_Q2_Rapporten_230810_SE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q2\\Pressmeddelande_Publicering_Q2_Rapporten_230810_SE.pdf", "content_type": "application/pdf", "size": 199011, "sha256": "0cccbfb31d5c257d36c0112ff80cecc6a6cf16c76512534a514346b566ce7c1f", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q2\\Pressmeddelande_Publicering_Q2_Rapporten_230810_SE.pdf", "filename": "Pressmeddelande_Publicering_Q2_Rapporten_230810_SE.pdf", "extension": ".pdf", "size": 199011, "sha256": "0cccbfb31d5c257d36c0112ff80cecc6a6cf16c76512534a514346b566ce7c1f", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q2\\extracted\\Pressmeddelande_Publicering_Q2_Rapporten_2308\\Pressmeddelande_Publicering_Q2_Rapporten_230810_SE.txt", "text_chars": 5665, "metadata": { "page_count": 3, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q2\\extracted\\Pressmeddelande_Publicering_Q2_Rapporten_2308\\Pressmeddelande_Publicering_Q2_Rapporten_230810_SE.extraction.json" } }, { "label": "Oncopeptides AB Delarsrapport Q2 2023.pdf", "url": "https://attachment.news.eu.nasdaq.com/a33a1b06248aa2692803318f12b2e541e", "final_url": "https://attachment.news.eu.nasdaq.com/a33a1b06248aa2692803318f12b2e541e", "filename": "Oncopeptides_AB_Delarsrapport_Q2_2023.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q2\\Oncopeptides_AB_Delarsrapport_Q2_2023.pdf", "content_type": "application/pdf", "size": 750016, "sha256": "511489b44ac646f8143b032624333f57f51857336a5eb25edf04a985afc0f883", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q2\\Oncopeptides_AB_Delarsrapport_Q2_2023.pdf", "filename": "Oncopeptides_AB_Delarsrapport_Q2_2023.pdf", "extension": ".pdf", "size": 750016, "sha256": "511489b44ac646f8143b032624333f57f51857336a5eb25edf04a985afc0f883", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q2\\extracted\\Oncopeptides_AB_Delarsrapport_Q2_2023\\Oncopeptides_AB_Delarsrapport_Q2_2023.txt", "text_chars": 33250, "metadata": { "page_count": 9, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q2\\extracted\\Oncopeptides_AB_Delarsrapport_Q2_2023\\Oncopeptides_AB_Delarsrapport_Q2_2023.extraction.json" } } ], "announcement_id": "1241808", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T06:12:25Z", "company": "Oncopeptides AB", "title": "Oncopeptides publishes Q1 report 2023", "category": "Interim report (Q1 and Q3)", "date": "2023-05-04", "language": "en", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "period": "2023-q1", "report_key": "2023:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b0ab52e703a4b7a0195a3d4299da0e1ef&lang=en&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q1\\release.txt", "attachments": [ { "label": "Press Release Publication Q1 Report 230504 EN.pdf", "url": "https://attachment.news.eu.nasdaq.com/aacda99572500bae00a9a9fa73b402245", "final_url": "https://attachment.news.eu.nasdaq.com/aacda99572500bae00a9a9fa73b402245", "filename": "Press_Release_Publication_Q1_Report_230504_EN.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q1\\Press_Release_Publication_Q1_Report_230504_EN.pdf", "content_type": "application/pdf", "size": 197370, "sha256": "75abe50dc1fc8268b413b734617df4535da61f9033be7990551b28442704eb4e", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q1\\Press_Release_Publication_Q1_Report_230504_EN.pdf", "filename": "Press_Release_Publication_Q1_Report_230504_EN.pdf", "extension": ".pdf", "size": 197370, "sha256": "75abe50dc1fc8268b413b734617df4535da61f9033be7990551b28442704eb4e", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q1\\extracted\\Press_Release_Publication_Q1_Report_230504_EN\\Press_Release_Publication_Q1_Report_230504_EN.txt", "text_chars": 4959, "metadata": { "page_count": 2, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q1\\extracted\\Press_Release_Publication_Q1_Report_230504_EN\\Press_Release_Publication_Q1_Report_230504_EN.extraction.json" } }, { "label": "Interim Report Q1 2023 ENG Oncopeptides.pdf", "url": "https://attachment.news.eu.nasdaq.com/a485b398b49174d0cba5f2f87aa103a27", "final_url": "https://attachment.news.eu.nasdaq.com/a485b398b49174d0cba5f2f87aa103a27", "filename": "Interim_Report_Q1_2023_ENG_Oncopeptides.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q1\\Interim_Report_Q1_2023_ENG_Oncopeptides.pdf", "content_type": "application/pdf", "size": 674335, "sha256": "e936c0643f451fbbc6ac9a1b48b71c0c4bcdf1f3b5eb2dde58ef2229954b2e00", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q1\\Interim_Report_Q1_2023_ENG_Oncopeptides.pdf", "filename": "Interim_Report_Q1_2023_ENG_Oncopeptides.pdf", "extension": ".pdf", "size": 674335, "sha256": "e936c0643f451fbbc6ac9a1b48b71c0c4bcdf1f3b5eb2dde58ef2229954b2e00", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q1\\extracted\\Interim_Report_Q1_2023_ENG_Oncopeptides\\Interim_Report_Q1_2023_ENG_Oncopeptides.txt", "text_chars": 29709, "metadata": { "page_count": 9, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\oncopeptides\\nasdaq-reports\\reports\\2023-q1\\extracted\\Interim_Report_Q1_2023_ENG_Oncopeptides\\Interim_Report_Q1_2023_ENG_Oncopeptides.extraction.json" } } ], "announcement_id": "1225336", "status": "retrieved" } ], "attempts": [ { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "92efd55415166a4c463828bce8a356b3a6eda6f3dc7784717137373c84851000" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 100, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "f95caef171e44e3b0e643da15f7ebb23052ee5eb19921bd04afbb0094b7ce781" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 200, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "94d6e7b614c0108fc94b6d0d4dda5b93abafe1aff9d8403106d25644e495bbb3" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=300&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 300, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 22, "new_rows": 22, "total_count": null, "from_cache": false, "body_sha256": "f1e9493b8306aad25d1202913eae97603ae214e3e4f107e03d5052e5ab89b941" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=322&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 322, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "c0cfc4afa4560873ce2c1e6ea479690fbb6ed063452e1a5f83e7f4688f8d3848" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 9, "new_rows": 9, "total_count": null, "from_cache": false, "body_sha256": "5af7f555cbc992791c6ddcea82254744d611c8d6b00340cac932bac1589edc81" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=9&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 9, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "b227fd681bfdae6ce68633fb45ef6c607d316d497c2c58e498345eb96cdebbe9" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "a1265eae9b62de3291d2987152210c5b6b66e23f3eee5116cf34a54a0d156eeb" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 100, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "90c4386b510c35ca4763497d42a360d224f2c15110360fb2e7f08626196aaae7" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 200, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "685fe6ad07bc89ac3283ee34f2a24d28fdbe884ca4a0b48a50da0db2d47b9f17" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=300&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 300, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 14, "new_rows": 14, "total_count": null, "from_cache": false, "body_sha256": "d0fbba1ab116b7fcd63aca80d853ec3a132a82dedfd3393609e7c0309b74f215" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=314&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 314, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "ce5d554b70776fc90321979d9a368364db230bee156a40e4c4e8470c6b4bb979" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 3, "new_rows": 3, "total_count": null, "from_cache": false, "body_sha256": "2add54113ea1d270485f9ecaf2a3b50b53523946d72babc3e022a5775a0bd03d" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Oncopeptides&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=3&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 3, "pagination": "row-offset", "query_text": "Oncopeptides", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "449de37c3458e07fa7a04e480e0ef1298d825283b8c7f36964108a8672015b9a" } ], "identity": { "slug": "", "instrument_id": "TX2304580", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/onco?id=TX2304580" }, "transport": "ordinary-http", "browser_used": false, "query_text": "Oncopeptides", "retrieved_at": "2026-08-07T06:12:26Z" }